Log in

NASDAQ:SPNE - SeaSpine Stock Price, Forecast & News

$16.07
-0.35 (-2.13 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$16.03
Now: $16.07
$16.68
50-Day Range
$12.51
MA: $15.21
$16.42
52-Week Range
$10.44
Now: $16.07
$18.53
Volume110,714 shs
Average Volume137,623 shs
Market Capitalization$306.45 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPNE
CUSIPN/A
Phone760-727-8399

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.44 million
Book Value$7.67 per share

Profitability

Net Income$-33,520,000.00

Miscellaneous

Employees361
Market Cap$306.45 million
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SPNE and its competitors with MarketBeat's FREE daily newsletter.


SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Corp (NASDAQ:SPNE) announced its quarterly earnings data on Tuesday, October, 29th. The medical equipment provider reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.08. The medical equipment provider had revenue of $39.89 million for the quarter, compared to analysts' expectations of $38.48 million. SeaSpine had a negative return on equity of 27.36% and a negative net margin of 26.22%. View SeaSpine's Earnings History.

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for SeaSpine.

How can I listen to SeaSpine's earnings call?

SeaSpine will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine issued an update on its fourth quarter 2019 After-Hours earnings guidance on Tuesday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $43.4-43.8 million, compared to the consensus revenue estimate of $42.16 million.

What price target have analysts set for SPNE?

4 Wall Street analysts have issued twelve-month target prices for SeaSpine's shares. Their forecasts range from $13.00 to $25.00. On average, they anticipate SeaSpine's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price. View Analyst Price Targets for SeaSpine.

What is the consensus analysts' recommendation for SeaSpine?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.

What are Wall Street analysts saying about SeaSpine stock?

Here are some recent quotes from research analysts about SeaSpine stock:
  • 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (1/18/2020)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $22 PT on SPNE. The strong execution that drove double-digit growth in 2H18 carried over into 2019 as SPNE posted 1Q revenue of $36MM (+9%), beating FactSet consensus by ~ $1MM, despite one less selling day, which we estimate likely created a 150bp headwind. SPNE is executing on its plan to add more exclusive distributors, increase proportion of revenue from recently launched products and progress against plan for staged launch of new products. SPNE raised the lower end of its 2019 sales guidance to $154-156MM (+7.5-9%), but we still consider guidance conservative and would not be surprised to see more beat and raises." (5/2/2019)
  • 3. BTIG Research analysts commented, "We reiterate our Buy rating and $20 PT on SPNE following investor meetings in New York. High level takeaways from meetings noted an encouraging cadence of new product introductions in FY19 and beyond, a growing proportion of committed and exclusive distributors supporting SPNE’s portfolio, access to capital (without the need for additional funds in the next 3 years), achievable guidance, and an inexpensive valuation (absolute and relative). While 1Q is typically a seasonally softer quarter in spine, the outlook for FY19 is encouraging and if 2H18 is indicative of the momentum SPNE is seeing amongst its distributors and customers then a few more quarters of consistent execution should have shares re-rating at an improved multiple. We like SPNE’s set-up in FY19 as all the key pieces are in place for improved and continued momentum." (3/31/2019)

Has SeaSpine been receiving favorable news coverage?

Media headlines about SPNE stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SeaSpine earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for SeaSpine.

Who are some of SeaSpine's key competitors?

What other stocks do shareholders of SeaSpine own?

Who are SeaSpine's key executives?

SeaSpine's management team includes the folowing people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
  • Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Carrie Mendivil, Head of Investor Relations
  • Mr. John J. Winge, VP of Sales (Age 52)

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (3.02%), Renaissance Technologies LLC (2.87%), State Street Corp (1.51%), Geode Capital Management LLC (1.03%), Essex Investment Management Co. LLC (0.71%) and Boston Partners (0.60%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Bradley, Keith Valentine, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for SeaSpine.

Which institutional investors are selling SeaSpine stock?

SPNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Falcon Point Capital LLC, Mackay Shields LLC, Alambic Investment Management L.P., Wedge Capital Management L L P NC, Boston Partners, Acadian Asset Management LLC and Strs Ohio. View Insider Buying and Selling for SeaSpine.

Which institutional investors are buying SeaSpine stock?

SPNE stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Renaissance Technologies LLC, Essex Investment Management Co. LLC, Jacobs Levy Equity Management Inc., Monarch Partners Asset Management LLC, Zebra Capital Management LLC, Barclays PLC and Trexquant Investment LP. View Insider Buying and Selling for SeaSpine.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $16.07.

How big of a company is SeaSpine?

SeaSpine has a market capitalization of $306.45 million and generates $143.44 million in revenue each year. The medical equipment provider earns $-33,520,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. SeaSpine employs 361 workers across the globe.View Additional Information About SeaSpine.

What is SeaSpine's official website?

The official website for SeaSpine is http://www.seaspine.com/.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]


MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel